Validation of the FACT-G7 in Patients with Hematologic Malignancies

Overview

Journal Front Oncol

Specialty Oncology

Date 2023 Aug 28

PMID 37637033

Authors

Xinwen Du

Ling Mao

Yamei Leng

Fengjiao Chen

Affiliations

Soon will be listed here.

Abstract

Background: It is essential to evaluate the quality of life in patients with hematologic malignancies to reflect the therapeutic effect and prognosis, but lengthy assessments are often burdensome. The 7-Item Functional Assessment of Cancer Therapy-General (FACT-G7) is a brief, easy, and rapid index for evaluating quality of life. Nevertheless, there is no report about its application in Chinese patients with hematologic malignancies.

Objective: The purpose of this study was to validate the Chinese version of the FACT-G7 for patients with hematologic malignancies.

Methods: This study is a cross-sectional study. A total of 855 patients with hematologic malignancies completed the Functional Assessment of Cancer Therapy-General (FACT-G) and were scored the Eastern Cooperative Oncology Group Performance Status (ECOG-PS) by nurses. Cronbach's alpha, confirmatory factor analyses, Pearson's correlation, and one-way analysis of variance were conducted to evaluate internal consistent reliability, structural validity and concurrent validity.

Results: The FACT-G7 showed acceptable internal consistency, as indicated by a Cronbach's alpha of 0.73. The confirmatory factor analyses test for single-factor model fit for the FACT-G7 scale was almost adequate. The satisfactory correlations between the FACT-G7 and the FACT-G and its subscales, and ECOG-PS groups differed in FACT-G7 scores demonstrating concurrent validity.

Conclusion: This study suggested that the Chinese version of the FACT-G7 provides a useful and rapid measure for assessing quality of life in Chinese patients with hematologic malignancies, which providing a reference for further evaluation and care.

Citing Articles

Impact of an Asian Community-Based Cancer Rehabilitation Program on Health-Related Quality of Life.

Tay M, Wong C, Chadachan V Healthcare (Basel). 2024; 12(22).

PMID: 39595449 PMC: 11593355. DOI: 10.3390/healthcare12222251.

Patient-Reported Sexual Function, Bladder Function and Quality of Life for Patients with Low Rectal Cancers with or without a Permanent Ostomy.

Rooney M, Pasli M, Chang G, Das P, Koay E, Koong A Cancers (Basel). 2024; 16(1).

PMID: 38201580 PMC: 10778006. DOI: 10.3390/cancers16010153.

References

Oken M, Creech R, Tormey D, Horton J, Davis T, McFadden E . Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5(6):649-55. View

Mah K, Swami N, Le L, Chow R, Hannon B, Rodin G . Validation of the 7-item Functional Assessment of Cancer Therapy-General (FACT-G7) as a short measure of quality of life in patients with advanced cancer. Cancer. 2020; 126(16):3750-3757. DOI: 10.1002/cncr.32981. View

So S, Ng D, Liao Q, Fielding R, Soong I, Chan K . Return to Work and Work Productivity During the First Year After Cancer Treatment. Front Psychol. 2022; 13:866346. PMC: 9039203. DOI: 10.3389/fpsyg.2022.866346. View

Vanbutsele G, Pardon K, Van Belle S, Surmont V, De Laat M, Colman R . Effect of early and systematic integration of palliative care in patients with advanced cancer: a randomised controlled trial. Lancet Oncol. 2018; 19(3):394-404. DOI: 10.1016/S1470-2045(18)30060-3. View

King M, Agar M, Currow D, Hardy J, Fazekas B, McCaffrey N . Assessing quality of life in palliative care settings: head-to-head comparison of four patient-reported outcome measures (EORTC QLQ-C15-PAL, FACT-Pal, FACT-Pal-14, FACT-G7). Support Care Cancer. 2019; 28(1):141-153. DOI: 10.1007/s00520-019-04754-9. View

Yu C, Fielding R, Chan C, Tse V, Choi P, Lau W . Measuring quality of life of Chinese cancer patients: A validation of the Chinese version of the Functional Assessment of Cancer Therapy-General (FACT-G) scale. Cancer. 2000; 88(7):1715-27. View

Andersen L, McHugh M, Ulrich C, Meghani S, Deng J . Coping Skills Interventions for Fatigue in Adults with Hematologic Malignancies: A Systematic Review. Am J Hosp Palliat Care. 2022; 40(2):183-201. PMC: 9637237. DOI: 10.1177/10499091221095531. View

Cella D, Tulsky D, Gray G, Sarafian B, Linn E, Bonomi A . The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993; 11(3):570-9. DOI: 10.1200/JCO.1993.11.3.570. View

Velikova G, Awad N, Coles-Gale R, Wright E, Brown J, Selby P . The clinical value of quality of life assessment in oncology practice-a qualitative study of patient and physician views. Psychooncology. 2007; 17(7):690-8. DOI: 10.1002/pon.1295. View

10.

Kang N, Kim H, Kim J, Kim S . Relationship between cancer stigma, social support, coping strategies and psychosocial adjustment among breast cancer survivors. J Clin Nurs. 2020; 29(21-22):4368-4378. DOI: 10.1111/jocn.15475. View

11.

Chen F, Leng Y, Ni J, Niu T, Zhang L, Li J . Symptom clusters and quality of life in ambulatory patients with multiple myeloma. Support Care Cancer. 2022; 30(6):4961-4970. DOI: 10.1007/s00520-022-06896-9. View

12.

Martin T, Huff C . Multiple Myeloma: Current Advances and Future Directions. Clin Lymphoma Myeloma Leuk. 2019; 19(5):255-263. DOI: 10.1016/j.clml.2019.03.025. View

13.

Kamal M, Wang X, Shi Q, Zyczynski T, Davis C, Williams L . Symptom burden and its functional impact in patients with "symptomatic" relapsed or refractory multiple myeloma. Support Care Cancer. 2020; 29(1):467-475. DOI: 10.1007/s00520-020-05493-y. View

14.

. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392(10159):1736-1788. PMC: 6227606. DOI: 10.1016/S0140-6736(18)32203-7. View

15.

Chen F, Leng Y, Zhang L, Xu J, Zhang D, Qin Y . The Correlation of Symptom Clusters and Functional Performance in Adult Acute Leukemia Patients Under Chemotherapy. Cancer Nurs. 2020; 44(5):E287-E295. DOI: 10.1097/NCC.0000000000000816. View

16.

Klaver K, Duijts S, Engelhardt E, Geusgens C, Aarts M, Ponds R . Cancer-related cognitive problems at work: experiences of survivors and professionals. J Cancer Surviv. 2019; 14(2):168-178. PMC: 7182611. DOI: 10.1007/s11764-019-00830-5. View

17.

von Elm E, Altman D, Egger M, Pocock S, Gotzsche P, Vandenbroucke J . The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007; 370(9596):1453-7. DOI: 10.1016/S0140-6736(07)61602-X. View

18.

Neeman E, Gresham G, Ovasapians N, Hendifar A, Tuli R, Figlin R . Comparing Physician and Nurse Eastern Cooperative Oncology Group Performance Status (ECOG-PS) Ratings as Predictors of Clinical Outcomes in Patients with Cancer. Oncologist. 2019; 24(12):e1460-e1466. PMC: 6975959. DOI: 10.1634/theoncologist.2018-0882. View

19.

Hochman M, Yu Y, Wolf S, Samsa G, Kamal A, LeBlanc T . Comparing the Palliative Care Needs of Patients With Hematologic and Solid Malignancies. J Pain Symptom Manage. 2017; 55(1):82-88.e1. PMC: 5921902. DOI: 10.1016/j.jpainsymman.2017.08.030. View

20.

Ramos C, Rouce R, Robertson C, Reyna A, Narala N, Vyas G . In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas. Mol Ther. 2018; 26(12):2727-2737. PMC: 6277484. DOI: 10.1016/j.ymthe.2018.09.009. View